Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Company Overview

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting.

Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.

Key Stats

• Today's Range: $5.83 to $6.07
• 50-Day Range: $4.23 to $6.01
• 52-Week Range: $4.00 to $7.54
• Volume: 1.84 million shs
• Average Volume: 1.03 million shs
• Market Capitalization: $341.85 million
• P/E Ratio: 5.84
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Moderate Buy

Abeona Therapeutics Stock Analysis - MarketRank™

Abeona Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 349th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Abeona Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Abeona Therapeutics has a consensus price target of $19.00, representing about 216.1% upside from its current price of $6.01.

Amount of Analyst Coverage

Abeona Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.60) to $0.55 per share.

Price to Book Value per Share Ratio

Abeona Therapeutics has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

31.10% of the float of Abeona Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Abeona Therapeutics has a short interest ratio ("days to cover") of 13.53, which indicates bearish sentiment.

Change versus previous month

Short interest in Abeona Therapeutics has recently increased by 3.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Abeona Therapeutics does not currently pay a dividend.

Dividend Growth

Abeona Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.74

News Sentiment

Abeona Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.

Search Interest

14 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Abeona Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of Abeona Therapeutics is held by insiders.

Percentage Held by Institutions

80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABEO Stock Analysis - Frequently Asked Questions

How have ABEO shares performed this year?

Abeona Therapeutics' stock was trading at $5.27 at the beginning of 2026. Since then, ABEO stock has increased by 14.0% and is now trading at $6.01.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc. (NASDAQ:ABEO) announced its earnings results on Tuesday, March, 17th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.01. The biopharmaceutical company earned $3 million during the quarter, compared to analyst estimates of $5.65 million.
Read the conference call transcript.

When did Abeona Therapeutics' stock split?

Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' top institutional investors include AIGH Capital Management LLC (5.45%) and Simplify Asset Management Inc. (0.89%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Madhav Vasanthavada, Leila Alland, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Mark Alvino and Eric Crombez.
View institutional ownership trends.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Abeona Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE).

Company Calendar

• Last Earnings: 3/17/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABEO
• Previous Symbol: OTCMKTS:ACCP
• CIK: 318306
• Web: www.abeonatherapeutics.com
• Phone: 214-665-9495
• Fax: 214-905-5101
• Employees: 90
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Abeona Therapeutics: $19.00
• High Price Target: $20.00
• Low Price Target: $17.00
• Potential Upside/Downside: +216.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.03
• Trailing P/E Ratio: 5.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $71.18 million
• Net Margins: N/A
• Pretax Margin: 1,224.79%
• Return on Equity: -60.65%
• Return on Assets: -40.78%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 6.93
• Quick Ratio: 6.74

Sales & Book Value

• Annual Sales: $5.82 million
• Price / Sales: 58.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.94 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 56,880,000
• Free Float: 52,958,000
• Market Cap: $341.85 million
• Optionable: Optionable
• Beta: 1.35